Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis.

Cotter TG, Charlton MR.

Hepatology. 2019 Mar;69(3):931-933. doi: 10.1002/hep.30408. Epub 2019 Feb 19. No abstract available.

PMID:
30570159
2.

International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation.

Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA.

Transplantation. 2019 Apr;103(4):733-746. doi: 10.1097/TP.0000000000002453.

PMID:
30335692
3.

Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.

Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, Mae Diehl A, Ghalib R, Elkhashab M, Abdelmalek MF, Kowdley KV, Stephen Djedjos C, Xu R, Han L, Mani Subramanian G, Myers RP, Goodman ZD, Afdhal NH, Charlton MR, Sirlin CB, Loomba R.

J Hepatol. 2019 Jan;70(1):133-141. doi: 10.1016/j.jhep.2018.09.024. Epub 2018 Oct 4.

4.

Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.

Sundaram V, Jalan R, Ahn JC, Charlton MR, Goldberg DS, Karvellas CJ, Noureddin M, Wong RJ.

J Hepatol. 2018 Sep;69(3):617-625. doi: 10.1016/j.jhep.2018.04.016. Epub 2018 Apr 28.

PMID:
29709681
5.

Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.

Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR.

World J Gastroenterol. 2018 Mar 28;24(12):1321-1331. doi: 10.3748/wjg.v24.i12.1321.

6.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

7.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

8.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators.

Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26. Erratum in: Hepatology. 2018 May;67(5):2063.

9.

Predictors of Cardiovascular Events After Liver Transplantation.

Gallegos-Orozco JF, Charlton MR.

Clin Liver Dis. 2017 May;21(2):367-379. doi: 10.1016/j.cld.2016.12.009. Epub 2017 Feb 20. Review.

PMID:
28364819
10.

Roadmap for improving patient and graft survival in the next 10 years.

Charlton MR.

Liver Transpl. 2016 Nov;22(S1):71-78. doi: 10.1002/lt.24602. No abstract available.

11.

Alcoholic Liver Disease and Liver Transplantation.

Gallegos-Orozco JF, Charlton MR.

Clin Liver Dis. 2016 Aug;20(3):521-34. doi: 10.1016/j.cld.2016.02.009. Review.

PMID:
27373614
12.

Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.

Billerbeck E, Mommersteeg MC, Shlomai A, Xiao JW, Andrus L, Bhatta A, Vercauteren K, Michailidis E, Dorner M, Krishnan A, Charlton MR, Chiriboga L, Rice CM, de Jong YP.

J Hepatol. 2016 Aug;65(2):334-43. doi: 10.1016/j.jhep.2016.04.022. Epub 2016 May 2.

13.

Nonalcoholic Fatty Liver Disease and Liver Transplantation.

Pham T, Dick TB, Charlton MR.

Clin Liver Dis. 2016 May;20(2):403-17. doi: 10.1016/j.cld.2015.10.014. Review.

PMID:
27063277
14.

Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H, Gores GJ.

Gastroenterology. 2016 Apr;150(4):956-67. doi: 10.1053/j.gastro.2015.12.037. Epub 2016 Jan 5.

15.

Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

Sundaram V, Kaung A, Rajaram A, Lu SC, Tran TT, Nissen NN, Klein AS, Jalan R, Charlton MR, Jeon CY.

Aliment Pharmacol Ther. 2015 Dec;42(11-12):1271-80. doi: 10.1111/apt.13426. Epub 2015 Oct 13.

16.

Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States.

Koning L, Charlton MR, Pas SD, Heimbach JK, Osterhaus AD, Watt KD, Janssen HL, de Knegt RJ, van der Eijk AA.

BMC Infect Dis. 2015 Sep 2;15:371. doi: 10.1186/s12879-015-1103-9.

17.

Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.

Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR.

Liver Int. 2015 Nov;35(11):2433-41. doi: 10.1111/liv.12890. Epub 2015 Jul 1.

PMID:
26058570
18.

A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.

Dick TB, Lindberg LS, Ramirez DD, Charlton MR.

Hepatology. 2016 Feb;63(2):634-43. doi: 10.1002/hep.27920. Epub 2015 Sep 21. Review.

PMID:
26033675
19.

Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.

Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR.

Liver Transpl. 2015 May;21(5):599-606. doi: 10.1002/lt.24117.

20.

Electrochemical modification of indium tin oxide using di(4-nitrophenyl) iodonium tetrafluoroborate.

Charlton MR, Suhr KJ, Holliday BJ, Stevenson KJ.

Langmuir. 2015 Jan 20;31(2):695-702. doi: 10.1021/la503522c. Epub 2015 Jan 7.

PMID:
25526354
21.

Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?

Gallegos-Orozco JF, Charlton MR.

Liver Int. 2015 Jan;35(1):9-11. doi: 10.1111/liv.12742. No abstract available.

PMID:
25412996
22.

Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.

Terzi E, Ray Kim W, Sanchez W, Charlton MR, Schmeltzer P, Gores GJ, Andrews JC, Smyrk TC, Heimbach JK.

Liver Transpl. 2015 Feb;21(2):248-57. doi: 10.1002/lt.24041.

23.

Broadly neutralizing antibodies abrogate established hepatitis C virus infection.

de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, Winer BY, Gerges S, Vega K, Labitt RN, Donovan BM, Giang E, Krishnan A, Chiriboga L, Charlton MR, Burton DR, Baltimore D, Law M, Rice CM, Ploss A.

Sci Transl Med. 2014 Sep 17;6(254):254ra129. doi: 10.1126/scitranslmed.3009512.

24.

Improving long-term outcomes after liver transplantation.

Charlton MR.

Clin Liver Dis. 2014 Aug;18(3):717-30. doi: 10.1016/j.cld.2014.05.011. Review.

PMID:
25017085
25.

Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size.

Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, Charlton MR.

Am J Transplant. 2014 Jun;14(6):1383-90. doi: 10.1111/ajt.12684. Epub 2014 May 6.

26.

Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events.

Watt KD, Fan C, Therneau T, Heimbach JK, Seaberg EC, Charlton MR.

Liver Transpl. 2014 Jul;20(7):791-7. doi: 10.1002/lt.23880. Epub 2014 May 26.

27.

Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease?

Guichelaar MM, Charlton MR.

Hepatology. 2014 May;59(5):1668-70. doi: 10.1002/hep.27058. Epub 2014 Apr 1. No abstract available.

PMID:
24691865
28.

Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C.

Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM.

Mayo Clin Proc. 2014 May;89(5):595-601. doi: 10.1016/j.mayocp.2014.01.024. Epub 2014 Mar 21.

29.

The impact of gender and NASH on chronic kidney disease before and after liver transplantation.

Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD.

Liver Int. 2014 Sep;34(8):1259-66. doi: 10.1111/liv.12381. Epub 2013 Nov 21.

PMID:
24262002
30.

Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.

Duarte-Rojo A, Budhraja V, Veldt BJ, Goldstein DD, Watt KD, Heimbach JK, McHutchison JG, Tillman HL, Poterucha JJ, Charlton MR.

Liver Transpl. 2013 Dec;19(12):1311-7. doi: 10.1002/lt.23733. Review.

31.

How important is acute cellular rejection?

Charlton MR.

Liver Transpl. 2013 Nov;19 Suppl 2:S9-13. doi: 10.1002/lt.23743. No abstract available.

32.

Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease.

Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR.

Am J Transplant. 2013 Sep;13(9):2450-7. doi: 10.1111/ajt.12355. Epub 2013 Jul 16.

33.

Serum albumin level is a notable profiling factor for non-B, non-C hepatitis virus-related hepatocellular carcinoma: A data-mining analysis.

Yamada S, Kawaguchi A, Kawaguchi T, Fukushima N, Kuromatsu R, Sumie S, Takata A, Nakano M, Satani M, Tonan T, Fujimoto K, Shima H, Kakuma T, Torimura T, Charlton MR, Sata M.

Hepatol Res. 2014 Aug;44(8):837-45. doi: 10.1111/hepr.12192. Epub 2013 Aug 4.

PMID:
23819517
34.
35.

Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival.

Singal AK, Kamath PS, Francisco Ziller N, DiCecco S, Shoreibah M, Kremers W, Charlton MR, Heimbach JK, Watt KD, Shah VH.

Transpl Int. 2013 Aug;26(8):788-94. doi: 10.1111/tri.12123. Epub 2013 Jun 11.

36.

Hepatic artery pseudoaneurysm formation following intraductal biliary radiofrequency ablation.

Topazian M, Levy MJ, Patel S, Charlton MR, Baron TH.

Endoscopy. 2013;45 Suppl 2 UCTN:E161-2. doi: 10.1055/s-0032-1326644. Epub 2013 May 28. No abstract available.

PMID:
23716112
37.

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.

Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP.

Liver Transpl. 2013 Jul;19(7):690-700. doi: 10.1002/lt.23669. Epub 2013 Jun 3.

38.

ChREBP in NASH - a liver transcription factor comes in from the cold.

Charlton MR.

J Hepatol. 2013 Jul;59(1):178-9. doi: 10.1016/j.jhep.2013.03.011. Epub 2013 Mar 21. No abstract available.

39.

Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.

Guichelaar MM, Gawrieh S, Olivier M, Viker K, Krishnan A, Sanderson S, Malinchoc M, Watt KD, Swain JM, Sarr M, Charlton MR.

Obesity (Silver Spring). 2013 Sep;21(9):1935-41. doi: 10.1002/oby.20327. Epub 2013 May 29.

40.

Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease.

Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM.

Am J Transplant. 2013 Feb;13(2):363-8. doi: 10.1111/j.1600-6143.2012.04318.x. Epub 2012 Nov 8.

41.

Nutrition in alcoholic liver disease.

Singal AK, Charlton MR.

Clin Liver Dis. 2012 Nov;16(4):805-26. doi: 10.1016/j.cld.2012.08.009. Review.

PMID:
23101983
42.

Interleukin-28B polymorphism in hepatitis C and liver transplantation.

Duarte-Rojo A, Deneke MG, Charlton MR.

Liver Transpl. 2013 Jan;19(1):49-58. doi: 10.1002/lt.23554.

43.

Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview.

Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, Charlton MR, Duarte-Rojo A.

Eur Respir Rev. 2012 Sep 1;21(125):223-33. doi: 10.1183/09059180.00007211.

44.

The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.

Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, Poterucha JJ, Vargas-Vorackova F, Charlton MR.

Transplantation. 2012 Jul 27;94(2):197-203. doi: 10.1097/TP.0b013e3182547551.

PMID:
22766768
46.

Introduction to the genetics and biology of interleukin-28B.

Urban T, Charlton MR, Goldstein DB.

Hepatology. 2012 Jul;56(1):361-6. doi: 10.1002/hep.25794. Review. No abstract available.

PMID:
22511448
47.

Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation.

Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR.

Liver Transpl. 2012 Jul;18(7):803-10. doi: 10.1002/lt.23424.

48.

Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C.

Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, Goldstein DD, McHutchison JG, Charlton MR.

Am J Transplant. 2012 Mar;12(3):737-44. doi: 10.1111/j.1600-6143.2011.03843.x. Epub 2012 Feb 2.

49.
50.

Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery.

Weingarten TN, Swain JM, Kendrick ML, Charlton MR, Schroeder BJ, Lee RE, Narr BJ, Ribeiro TC, Schroeder DR, Sprung J.

Obes Surg. 2011 Nov;21(11):1714-20. doi: 10.1007/s11695-011-0521-z.

PMID:
21948267

Supplemental Content

Loading ...
Support Center